Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicentre, Randomised, Double-masked, Vehicle-controlled, Parallel-arm, Phase 2 Study of the Safety and Efficacy of CA201A for the Prevention of Corneal Endothelial Cell Loss in Subjects Undergoing Cataract Surgery

NCT07694375 is registered in ClinicalTrials.gov with Caravel Oculus Pty Ltd as lead sponsor.

NCT NCT07694375
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07694375 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicentre, Randomised, Double-masked, Vehicle-controlled, Parallel-arm, Phase 2 Study of the Safety and Efficacy of CA201A for the Prevention of Corneal Endothelial Cell Loss in Subjects Undergoing Cataract Surgery
Lead sponsor
Caravel Oculus Pty Ltd
Phase
Phase 2
Overall status
Recruiting
Start date
July 28, 2026
Completion date
February 28, 2027
Enrollment
200 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

corneal endothelial cell loss, corneal endothelial damage following the hard nuclear cataract surgery